# The Critical Roles of Methyltransferase‐Like 3 in Atherosclerosis and Arterial Infarction: Breakthroughs in Mechanism Understanding

## TL;DR

This review explores how METTL3, a methyltransferase-like protein, influences atherosclerosis and arterial infarction, offering new insights into diagnosis and treatment.

## Contribution

This paper provides a comprehensive review of METTL3's role in atherosclerosis and arterial infarction, highlighting its potential as a biomarker and therapeutic target.

## Key findings

- METTL3 is identified as a risk factor for atherosclerosis and arterial infarction.
- RNA N6-modification by METTL3 is linked to disease pathogenesis and treatment resistance.
- Targeting METTL3 may offer new therapeutic strategies for these diseases.

## Abstract

Atherosclerosis (AS) and arterial infarction currently have a significant impact on human health. Due to their complex pathogenesis and lack of effective treatment approaches, patients worldwide experience high mortality rates. Methyltransferase‐like 3 (METTL3)‐mediated RNA N6‐modification has garnered considerable attention in elucidating the mechanisms underlying the pathogenesis and treatment failure of AS and arterial infarction. However, few reviews have explored the interrelationship between them. Therefore, this review aims to address this literature gap by evaluating all studies reporting on the involvement of METTL3 in AS and arterial infarction, as well as targeting METTL3 for rescuing these diseases. This review suggests that METTL3 serves as a risk factor, diagnostic biomarker and therapeutic target for AS and arterial infarction. Overall, it provides a comprehensive overview of cutting‐edge research on METTL3 in AS and arterial infarction, serving as a convenient reference for researchers in both basic and translational medicine fields.